ATHA vs. HOWL, ALVR, OKYO, MRSN, ICCC, MIST, ITRM, PRLD, RPTX, and CELU
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Werewolf Therapeutics (HOWL), AlloVir (ALVR), OKYO Pharma (OKYO), Mersana Therapeutics (MRSN), ImmuCell (ICCC), Milestone Pharmaceuticals (MIST), Iterum Therapeutics (ITRM), Prelude Therapeutics (PRLD), Repare Therapeutics (RPTX), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs.
Athira Pharma (NASDAQ:ATHA) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
In the previous week, Werewolf Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Werewolf Therapeutics and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Werewolf Therapeutics has higher revenue and earnings than Athira Pharma. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Athira Pharma has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Werewolf Therapeutics received 14 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 70.83% of users gave Werewolf Therapeutics an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote.
Athira Pharma currently has a consensus target price of $13.83, suggesting a potential upside of 5,433.33%. Werewolf Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,188.84%. Given Athira Pharma's higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Werewolf Therapeutics.
Athira Pharma has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat Athira Pharma's return on equity.
Summary
Werewolf Therapeutics beats Athira Pharma on 12 of the 16 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 4/6/2025 by MarketBeat.com Staff
Buy ATHA Stock Free ATHA Stock Alerts